Literature DB >> 30473497

Ethical challenges posed by human infection challenge studies in endemic settings.

Michael J Selgelid1, Euzebiusz Jamrozik2.   

Abstract

Human infection challenge studies (HCS) involve intentionally infecting research participants with pathogens, often with the ultimate aim of developing new interventions against infectious diseases. Despite ethical concerns about research involving vulnerable populations, there are both scientific and ethical reasons to consider conducting more HCS in low- and middle-income countries where neglected diseases are often endemic. HCS researchers can reduce the risks to participants (and the risks of transmission from participants to others) by controlling multiple factors (eg those related to the laboratory environment, participant selection, the pathogen, and the timing of treatment); but HCS nonetheless raise important ethical issues, some of which may be particularly pertinent to HCS in endemic settings. This article provides background on HCS in general, as well as recent HCS in low- and middle-income countries, and an overview of the ethical issues associated with HCS in endemic settings.

Entities:  

Mesh:

Year:  2018        PMID: 30473497      PMCID: PMC6785344          DOI: 10.20529/IJME.2018.073

Source DB:  PubMed          Journal:  Indian J Med Ethics        ISSN: 0974-8466


  23 in total

1.  The ethical challenge of infection-inducing challenge experiments.

Authors:  F G Miller; C Grady
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

2.  Regional distribution of beta-thalassemia mutations in India.

Authors:  I C Verma; R Saxena; E Thomas; P K Jain
Journal:  Hum Genet       Date:  1997-07       Impact factor: 4.132

Review 3.  Experimental human challenge infections can accelerate clinical malaria vaccine development.

Authors:  Robert W Sauerwein; Meta Roestenberg; Vasee S Moorthy
Journal:  Nat Rev Immunol       Date:  2011-01       Impact factor: 53.106

4.  Challenge studies of human volunteers: ethical issues.

Authors:  T Hope; J McMillan
Journal:  J Med Ethics       Date:  2004-02       Impact factor: 2.903

5.  Bioethics, vulnerability, and protection.

Authors:  Ruth Macklin
Journal:  Bioethics       Date:  2003-10       Impact factor: 1.898

6.  Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya.

Authors:  Susanne H Hodgson; Elizabeth Juma; Amina Salim; Charles Magiri; Daniel Njenga; Sassy Molyneux; Patricia Njuguna; Ken Awuondo; Brett Lowe; Peter F Billingsley; Andrew O Cole; Caroline Ogwang; Faith Osier; Roma Chilengi; Stephen L Hoffman; Simon J Draper; Bernhards Ogutu; Kevin Marsh
Journal:  Malar J       Date:  2015-04-28       Impact factor: 2.979

7.  Plasmodium vivax sporozoite challenge in malaria-naïve and semi-immune Colombian volunteers.

Authors:  Myriam Arévalo-Herrera; David A Forero-Peña; Kelly Rubiano; José Gómez-Hincapie; Nora L Martínez; Mary Lopez-Perez; Angélica Castellanos; Nora Céspedes; Ricardo Palacios; José Millán Oñate; Sócrates Herrera
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

8.  Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites.

Authors:  Seif Shekalaghe; Mastidia Rutaihwa; Peter F Billingsley; Mwajuma Chemba; Claudia A Daubenberger; Eric R James; Maximillian Mpina; Omar Ali Juma; Tobias Schindler; Eric Huber; Anusha Gunasekera; Anita Manoj; Beatus Simon; Elizabeth Saverino; L W Preston Church; Cornelus C Hermsen; Robert W Sauerwein; Christopher Plowe; Meera Venkatesan; Philip Sasi; Omar Lweno; Paul Mutani; Ali Hamad; Ali Mohammed; Alwisa Urassa; Tutu Mzee; Debbie Padilla; Adam Ruben; B Kim Lee Sim; Marcel Tanner; Salim Abdulla; Stephen L Hoffman
Journal:  Am J Trop Med Hyg       Date:  2014-07-28       Impact factor: 2.345

9.  Plasmodium vivax gametocyte infectivity in sub-microscopic infections.

Authors:  Andrés F Vallejo; Jhon García; Andrés B Amado-Garavito; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Malar J       Date:  2016-01-28       Impact factor: 2.979

10.  Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.

Authors:  Celina Jin; Malick M Gibani; Maria Moore; Helene B Juel; Elizabeth Jones; James Meiring; Victoria Harris; Jonathan Gardner; Anna Nebykova; Simon A Kerridge; Jennifer Hill; Helena Thomaides-Brears; Christoph J Blohmke; Ly-Mee Yu; Brian Angus; Andrew J Pollard
Journal:  Lancet       Date:  2017-09-28       Impact factor: 79.321

View more
  10 in total

1.  Ethical and practical considerations arising from community consultation on implementing controlled human infection studies using Schistosoma mansoni in Uganda.

Authors:  Moses Egesa; Agnes Ssali; Edward Tumwesige; Moses Kizza; Emmanuella Driciru; Fiona Luboga; Meta Roestenberg; Janet Seeley; Alison M Elliott
Journal:  Glob Bioeth       Date:  2022-07-04

Review 2.  Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy.

Authors:  Euzebiusz Jamrozik; Michael J Selgelid
Journal:  J Med Ethics       Date:  2020-05-07       Impact factor: 2.903

3.  Expert voices and equal partnerships: establishing Controlled Human Infection Models (CHIMs) in Vietnam.

Authors:  Evelyne Kestelyn; Chi Le Phuong; Jennifer Ilo Van Nuil; Hoai Tam Dong Thi; Nguyet Minh Nguyen; Trung Dinh The; Mary Chambers; Cameron P Simmons; Toan Nguyen Trong; Dung Nguyen The; Le Truc Phuong; Dung Do Van; Dung Duc Anh; Vinh Chau Nguyen Van; Stephen Baker; Bridget Wills
Journal:  Wellcome Open Res       Date:  2019-09-25

4.  When could human challenge trials be deployed to combat emerging infectious diseases? Lessons from the case of a Zika virus human challenge trial.

Authors:  Ricardo Palacios; Seema K Shah
Journal:  Trials       Date:  2019-12-19       Impact factor: 2.279

5.  Typhoidal Salmonella human challenge studies: ethical and practical challenges and considerations for low-resource settings.

Authors:  Meriel Raymond; Malick M Gibani; Nicholas P J Day; Phaik Yeong Cheah
Journal:  Trials       Date:  2019-12-19       Impact factor: 2.279

Review 6.  Human challenge trials in vaccine development.

Authors:  Amrita Sekhar; Gagandeep Kang
Journal:  Semin Immunol       Date:  2020-11-29       Impact factor: 11.130

7.  Engagement of ethics and regulatory authorities on human infection studies: Proceedings of an engagement workshop in Zambia.

Authors:  Evelyn Muleba Kunda-Ng'andu; Michelo Simuyandi; Melissa Kapulu; Masuzyo Chirwa-Chobe; Hope Mwanyungwi-Chinganya; Stanley Mwale; Roma Chilengi; Anjali Sharma
Journal:  Wellcome Open Res       Date:  2021-02-12

8.  Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.

Authors:  Nir Eyal
Journal:  Ethics Hum Res       Date:  2020-05-22

9.  Justifying the risks of COVID-19 challenge trials: The analogy with organ donation.

Authors:  Athmeya Jayaram; Jacob Sparks; Daniel Callies
Journal:  Bioethics       Date:  2021-06-27       Impact factor: 2.512

10.  Exploring willingness to participate in future Human Infection Studies in Lusaka, Zambia: A nested qualitative exploratory study.

Authors:  Evelyn Muleba Kunda-Ngándu; Masuzyo Chirwa-Chobe; Chanda Mwamba; Jenala Chipungu; Esnart Ng'andu; Hope Mwanyungwi Chinganya; Michelo Simuyandi; Roma Chilengi; Anjali Sharma
Journal:  PLoS One       Date:  2021-07-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.